NCT06107595 Conditioned Open Label Placebo for Postoperative Pain Management
| NCT ID | NCT06107595 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre de Médecine Intégrative et Complémentaire (CEMIC) |
| Condition | Pain, Postoperative |
| Study Type | INTERVENTIONAL |
| Enrollment | 222 participants |
| Start Date | 2024-01-15 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 222 participants in total. It began in 2024-01-15 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective is to evaluate the efficacy of two Conditioned Open Label Placebos (COLP): COLP pill and COLP odor to reduce opioid intake for postoperative (thoracic and spinal surgery) pain management compared to the opioid only usual treatment (TAU).
Eligibility Criteria
Inclusion Criteria: * Spinal or thoracic elective surgery for the indications mentioned above * Able to give informed consent * Interested in trying COLP as complementary pain management therapy * Able to fill a e-diary at home Exclusion Criteria: * Cognitive impairment (MOCA score \<26) * Inability to engage in the intervention of the study e.g. inability to communicate in French without a translator, severe hearing impairment without any hearing aid available at the time of intervention, anosmia or intolerance to eugenol. * Acute psychiatric (e.g. psychotic or suicidal ideation) or somatic (e.g. unstable cardio-respiratory condition) co-morbidity preventing full engagement during intervention * Opioid use disorder (toxicomania) or contraindication to pain management using opioids (allergy, refusal, ...) * Intolerance to placebo ingredients
Contact & Investigator
Chantal Berna Renella, Prof
PRINCIPAL INVESTIGATOR
Centre de Médecine Intégrative et Complémentaire, Lausanne University hospital
Frequently Asked Questions
Who can join the NCT06107595 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pain, Postoperative. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06107595 currently recruiting?
Yes, NCT06107595 is actively recruiting participants. Contact the research team at aurore.fernandez@chuv.ch for enrollment information.
Where is the NCT06107595 trial being conducted?
This trial is being conducted at Lausanne, Switzerland.
Who is sponsoring the NCT06107595 clinical trial?
NCT06107595 is sponsored by Centre de Médecine Intégrative et Complémentaire (CEMIC). The principal investigator is Chantal Berna Renella, Prof at Centre de Médecine Intégrative et Complémentaire, Lausanne University hospital. The trial plans to enroll 222 participants.